CERO 10-Q Quarterly Report Sept. 30, 2021 | Alphaminr
CERO THERAPEUTICS HOLDINGS, INC.
ALPHAMINR

CERO 10-Q Quarter ended Sept. 30, 2021

Balance Sheet
Cash Flow
Income Statement
10-Q
falseQ3--12-31000187040494612CA0.50.5This number includes an aggregate of up to 592,875 Class B common stock subject to forfeiture if the over-allotment option is not exercised in full or in part by the underwriter (see Note 5).Shares have been retroactively adjusted to reflect the recapitalization of the Company in the form of a 0.017-for-1 stock dividend (see Note 5).This number excludes an aggregate of up to 592,875 shares of Class B common stock subject to forfeiture if the over-allotment option is not exercised in full or in part by the underwriter (see Note 5).This number includes an aggregate of up to 592,875 shares of Class B common stock subject to forfeiture if the over-allotment option is not exercised in full or in part by the underwriter (see Note 5). 0001870404 2021-06-08 2021-09-30 0001870404 2021-09-30 0001870404 2021-09-30 2021-09-30 0001870404 2021-06-08 2021-06-30 0001870404 2021-07-01 2021-09-30 0001870404 2021-06-07 0001870404 2021-06-30 0001870404 us-gaap:CapitalUnitsMember 2021-06-08 2021-09-30 0001870404 us-gaap:CommonClassAMember 2021-06-08 2021-09-30 0001870404 us-gaap:WarrantMember 2021-06-08 2021-09-30 0001870404 srt:MinimumMember 2021-09-30 0001870404 pbax:InitialStockholdersMember 2021-09-30 0001870404 us-gaap:CommonClassBMember 2021-09-30 0001870404 us-gaap:CommonClassAMember 2021-09-30 0001870404 us-gaap:CommonClassBMember pbax:SponsorMember 2021-09-30 0001870404 pbax:PublicWarrantsMember pbax:WarrantsAndRightsSubjectToMandatoryRedemptionTriggerPriceExceedsOrEqualsToEighteenDollarsPerShareMember 2021-09-30 0001870404 us-gaap:CommonClassAMember pbax:PublicWarrantsMember pbax:WarrantsAndRightsSubjectToMandatoryRedemptionTriggerPriceExceedsOrEqualsToEighteenDollarsPerShareMember 2021-09-30 0001870404 us-gaap:CommonClassAMember pbax:PublicWarrantsMember pbax:EventTriggeringAdjustmentToExercisePriceOfWarrantsMember 2021-09-30 0001870404 pbax:PublicWarrantsMember 2021-09-30 0001870404 pbax:PublicWarrantsMember us-gaap:CommonClassAMember 2021-09-30 0001870404 pbax:PrivatePlacementWarrantsMember us-gaap:CommonClassAMember 2021-09-30 0001870404 pbax:UnderwriterAgreementMember 2021-09-30 0001870404 pbax:SponsorMember us-gaap:CommonClassAMember 2021-09-30 0001870404 pbax:SponsorMember pbax:WorkingCapitalLoansMember 2021-09-30 0001870404 pbax:SponsorMember pbax:PromissoryNoteMember 2021-09-30 0001870404 us-gaap:CommonClassBMember pbax:SponsorMember 2021-06-18 2021-06-18 0001870404 pbax:BusinessCombinationMember 2021-09-30 2021-09-30 0001870404 pbax:SponsorMember us-gaap:CommonClassBMember 2021-09-30 2021-09-30 0001870404 pbax:UnderwriterAgreementMember us-gaap:CommonClassBMember 2021-09-30 2021-09-30 0001870404 pbax:PublicWarrantsMember pbax:WarrantsAndRightsSubjectToMandatoryRedemptionTriggerPriceExceedsOrEqualsToEighteenDollarsPerShareMember us-gaap:CommonClassAMember 2021-09-30 2021-09-30 0001870404 us-gaap:CommonClassAMember pbax:PublicWarrantsMember pbax:EventTriggeringAdjustmentToExercisePriceOfWarrantsMember 2021-09-30 2021-09-30 0001870404 pbax:UnderwriterAgreementMember 2021-09-30 2021-09-30 0001870404 us-gaap:CommonClassBMember pbax:RecapitalizationMember 2021-09-30 2021-09-30 0001870404 us-gaap:CommonClassBMember pbax:SponsorMember pbax:RecapitalizationMember 2021-09-30 2021-09-30 0001870404 us-gaap:CommonClassAMember pbax:SponsorMember 2021-09-30 2021-09-30 0001870404 pbax:SponsorMember pbax:WorkingCapitalLoansMember 2021-09-30 2021-09-30 0001870404 us-gaap:SubsequentEventMember us-gaap:IPOMember 2021-10-08 2021-10-08 0001870404 pbax:SponsorMember us-gaap:SubsequentEventMember us-gaap:PrivatePlacementMember 2021-10-08 2021-10-08 0001870404 us-gaap:SubsequentEventMember us-gaap:OverAllotmentOptionMember 2021-10-08 2021-10-08 0001870404 us-gaap:SubsequentEventMember pbax:SponsorAndCohenAndCompanyCapitalMarketsMember us-gaap:PrivatePlacementMember 2021-10-08 2021-10-08 0001870404 us-gaap:SubsequentEventMember 2021-10-08 2021-10-08 0001870404 us-gaap:SubsequentEventMember us-gaap:CommonClassBMember pbax:SponsorMember 2021-10-08 2021-10-08 0001870404 pbax:InitialPublicOfferAndOverallotementMember us-gaap:SubsequentEventMember 2021-10-08 2021-10-08 0001870404 us-gaap:CommonClassAMember us-gaap:SubsequentEventMember us-gaap:IPOMember 2021-10-08 2021-10-08 0001870404 us-gaap:SubsequentEventMember us-gaap:CommonClassAMember us-gaap:OverAllotmentOptionMember 2021-10-08 2021-10-08 0001870404 us-gaap:SubsequentEventMember us-gaap:PrivatePlacementMember 2021-10-08 2021-10-08 0001870404 pbax:CantorFitzgeraldAndCoMember us-gaap:SubsequentEventMember us-gaap:PrivatePlacementMember 2021-10-08 2021-10-08 0001870404 pbax:CohenAndCompanyCapitalMarketsMember us-gaap:SubsequentEventMember us-gaap:PrivatePlacementMember 2021-10-08 2021-10-08 0001870404 us-gaap:SubsequentEventMember us-gaap:IPOMember pbax:UnderwriterAgreementMember 2021-10-08 2021-10-08 0001870404 us-gaap:SubsequentEventMember us-gaap:IPOMember 2021-10-08 0001870404 pbax:SponsorMember us-gaap:SubsequentEventMember us-gaap:PrivatePlacementMember 2021-10-08 0001870404 us-gaap:SubsequentEventMember pbax:InitialPublicOfferAndOverallotementMember 2021-10-08 0001870404 us-gaap:SubsequentEventMember us-gaap:OverAllotmentOptionMember 2021-10-08 0001870404 us-gaap:SubsequentEventMember 2021-10-08 0001870404 us-gaap:CommonClassAMember us-gaap:IPOMember us-gaap:SubsequentEventMember 2021-10-08 0001870404 us-gaap:SubsequentEventMember us-gaap:PrivatePlacementMember 2021-10-08 0001870404 us-gaap:SubsequentEventMember us-gaap:IPOMember pbax:UnderwriterAgreementMember 2021-10-08 0001870404 pbax:UnderwriterAgreementMember us-gaap:OverAllotmentOptionMember us-gaap:SubsequentEventMember 2021-10-08 0001870404 pbax:UnderwriterAgreementMember us-gaap:SubsequentEventMember pbax:InitialPublicOfferAndOverallotementMember 2021-10-08 0001870404 pbax:SponsorMember pbax:PromissoryNoteMember 2021-06-18 0001870404 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2021-07-01 2021-09-30 0001870404 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2021-07-01 2021-09-30 0001870404 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0001870404 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0001870404 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2021-06-08 2021-06-30 0001870404 us-gaap:CommonStockMember us-gaap:CommonClassBMember 2021-06-08 2021-06-30 0001870404 us-gaap:AdditionalPaidInCapitalMember 2021-06-08 2021-06-30 0001870404 us-gaap:RetainedEarningsMember 2021-06-08 2021-06-30 0001870404 us-gaap:CommonClassAMember 2021-11-19 0001870404 us-gaap:CommonClassBMember 2021-11-19 0001870404 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2021-09-30 0001870404 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2021-09-30 0001870404 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001870404 us-gaap:RetainedEarningsMember 2021-09-30 0001870404 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2021-06-07 0001870404 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2021-06-07 0001870404 us-gaap:AdditionalPaidInCapitalMember 2021-06-07 0001870404 us-gaap:RetainedEarningsMember 2021-06-07 0001870404 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2021-06-30 0001870404 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2021-06-30 0001870404 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001870404 us-gaap:RetainedEarningsMember 2021-06-30 xbrli:shares iso4217:USD utr:Day xbrli:pure utr:Month utr:Year iso4217:USD xbrli:shares
Table of Contents
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM
10-Q
 
 
(Mark One)
☒
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2021
 
☐
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from                     to                     
Commission File
No. 001-40877
 
 
PHOENIX BIOTECH ACQUISITION CORP.
(Exact name of registrant as specified in its charter)
 
 
 
Delaware
  
87-1088814
(State or other jurisdiction of
incorporation or organization)
  
(I.R.S. Employer
Identification No.)
2201 Broadway, Suite 705, Oakland, CA
(Address of Principal Executive Offices, including zip code)
(215) 731-9450
(Registrant’s telephone number, including area code)
N/A
(Former name, former address and former fiscal year, if changed since last report)
 
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
  
Trading
Symbol(s)
  
Name of each exchange
on which registered
Units, each consisting of one share of Class A common stock
and one-half of
one redeemable warrant
  
PBAXU
  
NASDAQ Global Market
Class A common stock, par value $0.0001 per share
  
PBAX
  
NASDAQ Global Market
Warrants, each whole warrant exercisable for one share of Class A common stock
  
PBAXW
  
NASDAQ Global Market
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes  ☐    No  ☒
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation
S-T
(§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes  ☒    No  ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
non-accelerated
filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule
12b-2
of the Exchange Act.
 
☐   Large accelerated filer    ☐   Accelerated filer
       
☒  
Non-accelerated
filer		    ☒   Smaller reporting company
       
         ☒   Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule
12b-2
of the Exchange Act):  Yes  ☒    No  ☐
As of
November
1
9
, 2021 there were 18,385,000
shares of Class A common stock, par value $0.0001 per share,
and 4,596,250
shares of Class B common stock, $0.0001 par value per share, issued and outstanding.
 
 
 
Table of Contents
PHOENIX BIOTECH ACQUISITION CORP.
Quarterly Report on Form
10-Q
TABLE OF CONTENTS
 
 
  
 
  
Page
 
PART 1 – FINANCIAL INFORMATION
  
Item 1.
  
  
  
  
 
1
 
  
  
 
2
 
  
  
 
3
 
  
  
 
4
 
  
  
 
5
 
Item 2.
  
  
 
13
 
Item 3.
  
  
 
16
 
Item 4.
  
  
 
16
 
  
 
16
 
Item 1.
  
  
 
16
 
Item 1A.
  
  
 
16
 
Item 2.
  
  
 
16
 
Item 3.
  
  
 
17
 
Item 4.
  
  
 
17
 
Item 5.
  
  
 
17
 
Item 6.
  
  
 
17
 
  
 
18
 
 
i
Item 1. Financial Statements
PHOENIX BIOTECH ACQUISITION CORP.
CONDENSED BALANCE SHEET (Unaudited)
September 30, 2021
 
ASSETS
         
CURRENT ASSETS
         
Cash
    $ —    
Prepaid expenses
      24,000  
    
 
 
  
Total current assets
      24,000  
    
 
 
  
OTHER ASSETS
         
Deferred offering costs
      277,000  
    
 
 
  
Total other assets
      277,000  
    
 
 
  
TOTAL ASSETS
   
$
301,000
  
    
 
 
  
LIABILITIES AND STOCKHOLDER’S EQUITY
         
CURRENT LIABILITIES
         
Accounts payable and accrued expenses
    $ 1,000  
Accrued offering costs
      276,000  
    
 
 
  
Total current liabilities
      277,000  
    
 
 
  
TOTAL LIABILITIES
     
277,000
  
    
 
 
  
COMMITMENTS AND CONTINGENCIES
      
STOCKHOLDER’S EQUITY
         
Preferred stock, $0.0001 par value; 1,000,000 shares authorized; none issued or outstanding
      —    
Class A common stock; $0.0001 par value; 60,000,000 shares authorized; none issued and outstanding
      —    
Class B common stock; $0.0001 par value; 10,000,000 shares authorized; 4,679,125 issued and outstanding (1) (2)
      467  
Additional
paid-in
capital
      24,533  
Accumulated deficit
      (1,000 ) 
    
 
 
  
TOTAL STOCKHOLDER’S EQUITY
      24,000  
    
 
 
  
TOTAL LIABILITIES AND STOCKHOLDER’S EQUITY
   
$
301,000
  
    
 
 
  
 
(1)
This number includes an aggregate of up to 592,875 shares of Class B common stock subject to forfeiture if the over-allotment option is not exercised in full or in part by the underwriter (see Note
5
).
(2)
Shares have been retroactively adjusted to reflect the recapitalization of the Company in the
f
orm of a 0.017-for-1 stock dividend (see Note
5
)
.
The accompanying notes are an integral part of the unaudited condensed financial statements.
 
1
Table of Contents
PHOENIX BIOTECH ACQUISITION CORP.
CONDENSED STATEMENTS OF OPERATIONS
(Unaudited)
 
    
Three Months Ended
September 30, 2021
    
For the period
June 8, 2021
(inception)
through
September 30,
2021
  
                  
EXPENSES
                 
Organizational costs
    $ —       $ 1,000  
    
 
 
    
 
 
  
Total expenses
      —         1,000  
    
 
 
    
 
 
  
NET LOSS
    $ —       $ (1,000 ) 
    
 
 
    
 
 
  
WEIGHTED
-
AVERAGE SHARES OUTSTANDING, BASIC AND DILUTED (1) (2)
      4,086,250       4,086,250  
    
 
 
    
 
 
  
BASIC AND DILUTED NET LOSS PER SHARE
    $ (0.00 )    $ (0.00 ) 
    
 
 
    
 
 
  
 
(1)
This number excludes an aggregate of up to 592,875 shares of Class B common stock subject to forfeiture if the over-allotment option is not exercised in full or in part by the underwriter (see Note
5
).
(2)
Shares have been retroactively adjusted to reflect the recapitalization of the Company in the
f
orm of a 0.017-for-1 stock dividend (see Note
 
5
)
.
The accompanying notes are an integral part of the unaudited condensed financial statements.
 
2
Table of Contents
PHOENIX BIOTECH ACQUISITION CORP.
CONDENSED STATEMENT OF CHANGES IN STOCKHOLDER’S EQUITY (Unaudited)
For the period June 8, 2021 (inception) through September 30, 2021
 
    
Common stock
                      
    
Class A Common Stock
     
Class B Common Stock
                  
Total
  
                                
Additional
     
Accumulated
    
stockholder’s
  
    
Shares
     
Amount
     
Shares
     
Amount
     
paid-in capital
     
deficit
    
equity
  
Balance, June 8, 2021 (inception)
      —        $ —          —        $ —        $ —        $ —       $ —    
Issuance of Class B common stock to Sponsor (1) (2)
      —          —          4,679,125        467        24,533        —         25,000  
Net loss
      —          —          —          —          —          (1,000 )      (1,000 ) 
    
 
 
     
 
 
     
 
 
     
 
 
     
 
 
     
 
 
    
 
 
  
Balance, June 30, 2021
      —       
$
 —          4,679,125      $ 467      $ 24,533      $ (1,000 )    $ 24,000  
Net loss
      —          —          —          —          —          —         —    
    
 
 
     
 
 
     
 
 
     
 
 
     
 
 
     
 
 
    
 
 
  
Balance, September 30, 2021
      —        $ —          4,679,125      $ 467      $ 24,533      $ (1,000 )    $ 24,000  
    
 
 
     
 
 
     
 
 
     
 
 
     
 
 
     
 
 
    
 
 
  
 
(1)
This number includes an aggregate of up to 592,875 Class B common stock subject to forfeiture if the over-allotment option is not exercised in full or in part by the underwriter (see Note
5
).
(2)
Shares have been retroactively adjusted to reflect the recapitalization of the Company in the
f
orm of a 0.017-for-1 stock dividend (see Note
5
)
.
The accompanying notes are an integral part of the unaudited condensed financial statements.
 
3
Table of Contents
PHOENIX BIOTECH ACQUISITION CORP.
CONDENSED STATEMENT OF CASH FLOWS
(Unaudited)
For the period June 8, 2021 (inception) through September 30, 2021
 
CASH FLOWS FROM OPERATING ACTIVITIES:
         
Net loss
    $ (1,000 ) 
Adjustments to reconcile net loss to net cash used in operating activities:
         
Accounts payable and accrued
expenses
      1,000  
    
 
 
  
NET CHANGE IN CASH
      —    
    
 
 
  
CASH, BEGINNING OF PERIOD
      —    
    
 
 
  
CASH, END OF PERIOD
    $ —    
    
 
 
  
Supplemental disclosure of noncash activities:
         
Deferred offering costs included in accrued offering
costs
    $ 276,000  
    
 
 
  
The accompanying notes are an integral part of the unaudited condensed financial statements.
 
4
Table of Contents
PHOENIX BIOTECH ACQUISITION CORP.
NOTES TO CONDENSED FINANCIAL STATEMENTS
SEPTEMBER 30, 2021
(Unaudited)
Note 1 – Description of Organization and Business Operations
Phoenix Biotech Acquisition Corp. (the “Company”) was incorporated in Delaware on June 8, 2021. The Company was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses (the “Business Combination”).
The Company is not limited to a particular industry or geographic region for purposes of consummating a Business Combination. The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies.
As of September 30, 2021, the Company had not commenced any operations. All activity through September 30, 2021 relates to the Company’s formation and Initial Public Offering (“IPO”), which is described below and, since the IPO, the search for a prospective initial Business Combination. The Company will not generate any operating revenues until after the completion of its initial Business Combination, at the earliest. The Company will
generate non-operating income
in the form of interest income earned on investments from the proceeds derived from the IPO. The registration statement for the Company’s IPO was declared effective on October 5, 2021. On October 8, 2021, the Company consummated the IPO of 15,500,000
units (“Units”) (with respect to the Class A common stock included in the Units being offered (the “Public Shares”)) at
$10.00 per Unit generating gross proceeds of $155,000,000, which is discussed in Note 3. The
Company 
has selected December 31 as its fiscal year end.
Simultaneously with the closing of the IPO, the Company consummated the sale of 845,000 units (“Private Placement Units”) at a price of $10.00
per Private Placement Unit in a private placement to the Company’s sponsor, Phoenix Biotech Sponsor, LLC (the “Sponsor”), Cantor Fitzgerald & Co. (“Cantor”) and Cohen & Company Capital Markets, a division of J.V.B. Financial Group, LLC (“CCM”), generating gross proceeds of
$8,450,000, which is described in Note 4.
Offering costs for the IPO amounted to $11,329,318, consisting of $2,635,000 of underwriting fees, $7,750,000 of deferred underwriting fees payable (which are held in the Trust Account (defined below)) and $944,318 of other costs. As described in Note 6, the $9,150,000 of deferred underwriting fee payable is contingent upon the consummation of a Business Combination by January 8, 2023, subject to the terms of the underwriting agreement.
Simultaneously with the closing of the IPO, the Company consummated the closing of the sale of 2,000,000
additional Units upon receiving notice of the underwriter’s election to partially exercise its over-allotment option (“Over-allotment Units”), generating additional gross proceeds of
$20,000,000 and incurring additional offering costs of $1,400,000
in underwriting fees, all of which is deferred until the completion of the Company’s initial Business Combination. Simultaneously with the exercise of the over-allotment, the Company consummated the Private Placement of an
additional 40,000 Private Placement Units to the Sponsor and CCM, generating gross proceeds of $400,000.
Following the closing of the IPO, $178,500,000 ($10.20
per Unit) from the net proceeds of the sale of the Units in the IPO, the Over-allotment Units and the Private Placement Units was placed in a trust account (“Trust Account”) and will be invested in U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act of 1940, as amended (the “Investment Company Act”), with a maturity
of 185 days or less or in money market funds meeting the conditions of the Investment Company Act, as determined by the Company, until the earlier of: (i) the completion of a Business Combination and (ii) the distribution of the Trust Account, as described below.
 
5
Table of Contents
The Company’s management has broad discretion with respect to the specific application of the net proceeds of the IPO and the sale of the Private Placement Units, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. There is no assurance that the Company will be able to complete a Business Combination successfully. The Company must complete one or more initial Business Combinations having an aggregate fair market value of at least 80% of the assets held in the Trust Account (excluding the deferred underwriting commissions and taxes payable on income earned on the Trust Account) at the time of the agreement to enter into the initial Business Combination. However, the Company will only complete a Business Combination if the post-transaction company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act. There is no assurance the Company will be able to successfully effect a Business Combination.
The Company will provide the holders of the outstanding Public Shares (the “Public Stockholders”) with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i) in connection with a stockholder meeting called to approve the Business Combination or (ii) by means of a tender offer. The decision as to whether the Company will seek stockholder approval of a Business Combination or conduct a tender offer will be made by the Company. The Public Stockholders will be entitled to redeem their Public Shares for a pro rata portion of the amount then in the Trust Account (initially anticipated to be $10.20 per Public Share, plus any pro rata interest then in the Trust Account, net of taxes payable). There will be no redemption rights with respect to the Company’s warrants.
All of the Public Shares contain a redemption feature which allows for the redemption of such Public Shares in connection with the Company’s liquidation, if there is a stockholder vote or tender offer in connection with the Company’s Business Combination and in connection with certain amendments to the Company’s amended and restated certificate of incorporation (the “Certificate of Incorporation”). In accordance with the rules of the U.S. Securities and Exchange Commission (the “SEC”) and its guidance on redeemable equity instruments, which has been codified in Accounting Standards Codification
(“ASC”) 480-10-S99, redemption
provisions not solely within the control of a company require common stock subject to redemption to be classified outside of permanent equity. Given that the Public Shares were issued with other freestanding instruments (i.e., public warrants), the initial carrying value of Class A common stock classified as temporary equity will be the allocated proceeds determined in accordance with
ASC 470-20. The
Class A common stock is subject to
ASC 480-10-S99. If
it is probable that the equity instrument will become redeemable, the Company has the option to either (i) accrete changes in the redemption value over the period from the date of issuance (or from the date that it becomes probable that the instrument will become redeemable, if later) to the earliest redemption date of the instrument or (ii) recognize changes in the redemption value immediately as they occur and adjust the carrying amount of the instrument to equal the redemption value at the end of each reporting period. The Company has elected to recognize the changes immediately. The accretion or remeasurement will be treated as a deemed dividend (i.e., a reduction to retained earnings, or in absence of retained earnings,
additional paid-in capital).
While redemptions cannot cause the Company’s net tangible assets to fall below $5,000,001, the Public Shares are redeemable and are classified as such on the balance sheet until such date that a redemption event takes place.
Redemptions of the Company’s Public Shares may be subject to the satisfaction of conditions, including minimum cash conditions, pursuant to an agreement relating to the Company’s Business Combination. If the Company seeks stockholder approval of the Business Combination, the Company will proceed with a Business Combination if a majority of the shares voted are voted in favor of the Business Combination, or such other vote as required by law or stock exchange rule. If a stockholder vote is not required by applicable law or stock exchange listing requirements and the Company does not decide to hold a stockholder vote for business or other reasons, the Company will, pursuant to its Certificate of Incorporation, conduct the redemptions pursuant to the tender offer rules of the SEC and file tender offer documents with the SEC prior to completing a Business Combination. If, however, stockholder approval of the transaction is required by applicable law or stock exchange listing requirements, or the Company decides to obtain stockholder approval for business or other reasons, the Company will offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. If the Company seeks stockholder approval in connection with a Business Combination, the Sponsor has agreed to vote its Founder Shares (as defined in Note 5) and any Public Shares purchased during or after the IPO in favor of approving a Business Combination. Additionally, each Public Stockholder may elect to redeem their Public Shares without voting, and if they do vote, irrespective of whether they vote for or against the proposed transaction.
 
6
Table of Contents
Notwithstanding the foregoing, the Certificate of Incorporation provides that a Public Stockholder, together with any affiliate of such stockholder or any other person with whom such stockholder is acting in concert or as a “group” (as defined under Section 13 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), will be restricted from redeeming its shares with respect to more than an aggregate of 15% or more of the Class A common stock sold in the IPO, without the prior consent of the Company.
The Company’s Sponsor, officers and directors (the “Initial Stockholders”) have agreed not to propose an amendment to the Certificate of Incorporation that would affect the substance or timing of the Company’s obligation to
redeem 100% of its Public Shares if the Company does not complete a Business Combination within the Combination Period (defined below), unless the Company provides the Public Stockholders with the opportunity to redeem their shares of Class A common stock in conjunction with any such amendment.
If the Company is unable to complete a Business Combination by January 8, 2023, 15
months from the closing of the IPO (the “Combination Period”), the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem the Public Shares, at
a per-share price,
payable in cash, equal to the aggregate amount then on deposit in the Trust Account including interest earned on the funds held in the Trust Account and not previously released to the Company to pay the Company’s franchise and income taxes (less up to
$100,000
of interest to pay dissolution expenses), divided by the number of then outstanding Public Shares, which redemption will completely extinguish Public Stockholders’ rights as stockholders (including the right to receive further liquidating distributions, if any), subject to applicable law, and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the Company’s remaining stockholders and the Company’s board of directors, dissolve and liquidate, subject in each case to the Company’s obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law.
The Initial Stockholders have agreed to waive their liquidation rights with respect to the Founder Shares if the Company fails to complete a Business Combination within the Combination Period. However, if the Initial Stockholders should acquire Public Shares in or after the IPO, they will be entitled to liquidating distributions from the Trust Account with respect to such Public Shares if the Company fails to complete a Business Combination within the Combination Period. The underwriter as agreed to waive its rights to the deferred underwriting commission (see Note 6) held in the Trust Account in the event the Company does not complete a Business Combination within the Combination Period and, in such event, such amounts will be included with the other funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such
distribution, it is possible that the per share value of the residual assets remaining available for distribution (including Trust Account assets) will be only
 
$10.20
per share held in the Trust Account. In order to protect the amounts held in the Trust Account, the Sponsor has agreed to be liable to the Company if and to the extent any claims by a vendor for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account. This liability will not apply with respect to any claims by a third party who executed a waiver of any right, title, interest or claim of any kind in or to any monies held in the Trust Account or to any claims under the Company’s indemnity of the underwriter of the IPO against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”). Moreover, in the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third-party claims. The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers (except the Company’s independent registered public accounting firm), prospective target businesses or other entities with which the Company does business, execute agreements waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account. 
Liquidity and Management’s Plans
Prior to the completion of the Initial Public Offering, the Company lacked the liquidity it needed to sustain operations for a reasonable period of time, which is considered to be one year from the issuance date of the unaudited condensed financial statements. The Company has since completed its Initial Public Offering at which time capital in excess of the funds deposited in the Trust Account and/or used to fund offering expenses was released to the Company for general working capital purposes. Accordingly, management has since reevaluated the Company’s liquidity and financial condition and determined that sufficient capital exists to sustain operations for at least one year from the date that the unaudited condensed financial statements were issued, and therefore substantial doubt has been alleviated.
Risks and Uncertainties
Management continues to evaluate the impact of the COVID-19 pandemic and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company’s financial position, results of operations and/or search for a target business, the specific impact is not readily determinable as of the date of these unaudited condensed financial statements. The unaudited condensed financial statements do not include any adjustments that might result from the outcome of this uncertainty.
Note 2 — Summary of Significant Accounting Policies
Basis of Presentation
The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X of the SEC. Certain information or footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited condensed financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented.
The accompanying unaudited condensed financial statements should be read in conjunction with the Company’s prospectus for its Initial Public Offering as filed with the SEC on October 8, 2021 as well as the Company’s Current Report on Form 8-K, as filed with the SEC on October 15, 2021. The interim results for the three months and period of June 8, 2021 (inception) through September 30, 2021 are not necessarily indicative of the results to be expected for the year ending December 31, 2021 or for any future periods.
 
7
Table of Contents
Emerging Growth Company
The Company is an emerging growth company as defined in Section 102(b)(1) of the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), which exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply
to non-emerging growth
companies but any such an election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which means that when a standard is issued or revised, and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard.
This may make comparison of the Company’s unaudited condensed financial statements with another public company that is neither an emerging growth company nor an emerging growth company that has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.
Cash and Cash Equivalents
The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company did not have any cash equivalents as of September 30, 2021.
Offering Costs
Offering costs, including additional underwriting fees associated with the underwriter’s exercise of the over-allotment option, consist principally of legal, accounting, underwriting fees and other costs directly related to the IPO. Offering costs, including those attributable to the underwriter’s partial exercise of the over-allotment option, amounted to
$12,729,318.
This amount was charged to stockholders’ deficit upon the completion of the IPO. As of September 30, 2021, offering costs were $277,000.
Concentration of Credit Risk
Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Deposit Insurance Corporation coverage limit of $250,000. At September 30, 2021, the Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such account.
Financial Instruments
The fair value of the Company’s assets and liabilities, which qualify as financial instruments under Financial Accounting Standards Board (“FASB”) ASC 820, “Fair Value Measurements and Disclosures,” approximates the carrying amounts represented in the accompanying unaudited condensed balance sheet, primarily due to their short-term nature.
Use of Estimates
The preparation of financial statements in conformity with U.S. GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statement
s
and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.
Income Taxes
The Company complies with the accounting and reporting requirements of FASB ASC Topic 740, “Income Taxes” (“FASB ASC 740”), which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed for differences between the financial statement and tax bases of assets and liabilities that will result in future taxable or deductible amounts, based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.
 
8
Table of Contents
FASB ASC 740 prescribes a recognition threshold
and
a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. There were
 
no
unrecognized tax benefits as of September 30, 2021. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. No amounts were accrued for the payment of interest and penalties for the period from June 8, 2021 (inception) through September 30, 2021. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception.
Recent Accounting Pronouncements
The Company’s management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s unaudited condensed financial statements.
Note 3 — Initial Public Offering
Pursuant to the IPO, the Company sold 17,500,000 units (including 2,000,000
units as part of the underwriter’s partial exercise of the over-allotment option) at a price of
$10.00 per Unit. Each Unit consists of one share of Class A common stock (such shares of Class A common stock included in the Units being offered, the “Public Shares”),
and one-half a
redeemable warrant (each, a “Public Warrant”). Each Public Warrant entitles the holder to purchase one share of Class A common stock at a price of $11.50 per share, subject to adjustment (see Note 7).
Note 4 — Private Placement
On October 8, 2021, simultaneously with the consummation of the IPO, the Company consummated the issuance and sale (“Private Placement”) of 885,000 Units (the “Placement Units”) in a private placement transaction at a price of $10.00 per Placement Unit, generating gross proceeds of $8,850,000. The Placement Units were purchased by Cantor (155,000 Units), CCM (30,004 Units)
and the 
Sponsor (699,996 Units). Each whole Placement Unit consists of one placement share
and one-half of
a redeemable warrant (“Placement Warrant”). Each whole Placement Warrant will be exercisable to purchase one share of Class A common stock at a price of $11.50 per share. A portion of the proceeds from the Placement Units was added to the proceeds from the IPO to be held in the Trust Account. If the Company does not complete a Business Combination within the Combination Period, the proceeds from the sale of the Placement Units will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law), and the Placement Units and all underlying securities will be worthless.
Note 5 — Related Party Transactions
Founder Shares
On June 18, 2021, the Sponsor provided funds to pay for certain costs totaling $25,000 on behalf of the Company as consideration for 4,598,750 shares of Class B common stock (the “Founder Shares”). In September 2021, the Company effected a 0.017
-for-1 stock 
dividend for each share of Class B common stock outstanding, and, as a result, the Sponsor holds 4,679,125
Founder Shares. As a result, the Company’s shares have been retroactively adjusted for this stock dividend; however, due to the shares being closely held the corresponding earnings have not been capitalized from accumulated deficit. The Sponsor agreed to forfeit up 
to 592,875 Founder Shares to the extent that
the
 
45-day 
over-allotment
option was not exercised in full by the underwriter. Since the underwriter exercised the over-allotment option only
in part, the Sponsor forfeited 
82,875 Founder Shares.
The Sponsor has agreed, subject to limited exceptions, not to transfer, assign or sell any of the Founder Shares until the earliest of: (a) one year after the completion of a Business Combination and (b) subsequent to a Business Combination, (x) if the closing price of the shares of Class A common stock equals or exceeds $12.00 per share (as adjusted) for any 20 trading days within
any
 
30
-trading-day 
period commencing at least 150 days after a Business Combination, or (y) the date on which the Company completes a liquidation, merger, share exchange or other similar transaction that results in all of the Public Stockholders having the right to exchange their shares of Class A common stock for cash, securities or other property.
 
9
Table of Contents
Related Party Loans
On June 18, 2021, the Sponsor agreed to loan the Company an aggregate of up to $300,000 to cover expenses related to the IPO pursuant to a promissory note which was amended on September 10, 2021 (as amended, the “Note”). This loan in
non-interest-bearing.
The Company had no
borrowings under the Note as of
September 30, 2021.
In addition, in order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company’s officers and directors may, but are not obligated to, loan the Company funds as may be required (“Working Capital Loans”). If the Company completes a Business Combination, the Company would repay the Working Capital Loans out of the proceeds of the Trust Account released to the Company. Otherwise, the Working Capital Loans would be repaid only out of funds held outside the Trust Account. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. Except for the foregoing, the terms of such Working Capital Loans, if any, have not been determined and no written agreements exist with respect to such loans. The Working Capital Loans would either be repaid upon consummation of a Business Combination, without interest, or, at the lender’s discretion, up to $1.5 million of such Working Capital Loans may be
converted
into units of the post Business Combination entity at a price of $10.00 per unit. The units would be identical to the Placement Units.
Support Services
The Company entered into an agreement, commencing on the date of its listing on Nasdaq through the earlier of the consummation of a Business Combination and the Company’s liquidation, to pay an affiliate of the Sponsor a monthly fee of $20,000
for office space, and secretarial and administrative services.
Note 6 — Commitments and Contingencies
Registration Rights
The holders of Founder Shares, Placement Units (including securities contained therein) and units that may be issued upon conversion of Working Capital Loans, if any, are entitled to registration rights (in the case of the Founder Shares, only after conversion of such shares to shares of Class A common stock) pursuant to a registration rights agreement dated October 5, 2021. These holders are entitled to certain demand and “piggyback” registration rights. However, the registration rights agreement provides that the Company will not permit any registration statement filed under the Securities Act to become effective until the termination of the
applicable lock-up period
for the securities to be registered. The Company will bear the expenses incurred in connection with the filing of any such registration statements.
Underwriting Agreement
The Company granted the underwriter
a 45-day
 
option
from the date of the final prospectus relating to the IPO to purchase up to 2,325,000
additional Units to cover over-allotments, if any, at the IPO price less the underwriting discounts and commissions. On October 8, 2021, the underwriter partially exercised its over-allotment option and
purchased 2,000,000 units at $10.00 per unit.
The underwriter was paid a cash underwriting discount of
$0.20 per unit, or $3,100,000 in the aggregate at the closing of the IPO, of which $465,000 was reimbursed to the Company to pay for additional advisors.
The underwriter agreed to defer any additional fees related to the exercise of the over-allotment option until the Company completes a Business Combination. As such,
$400,000 of additional underwriting fees related to the over-allotment have been deferred. In addition, the underwriters are entitled to a deferred underwriting commissions of $0.50 per unit, or $8,750,000 ($9,150,000 in the aggregate when including the $400,000 noted above) from the closing of the IPO. The deferred fee will become payable to the underwriters from the amounts held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement.
 
10
Table of Contents
Note 7 — Stockholder’s Equity
Common Stock
Class
 A common stock
 — The Company is authorized to issue 60,000,000 shares of Class A common stock with a par value of $0.0001 per share. As of September 
30
, 2021, there were no Class A common stock issued and outstanding.
Class
 B common stock
 — The Company is authorized to issue 10,000,000 shares of Class B common stock with a par value of $0.0001 per share. Holders of Class B common stock are entitled to one vote for each share. As of September 30, 2021, there were 4,679,125
shares of Class B common stock outstanding. The Sponsor agreed to forfeit up to
 592,875
Founder Shares to the extent that the 45-day over-allotment option was not exercised in full by the underwriter. Since the underwriter exercised the over-allotment option only in part, the Sponsor did forfeit 82,875 Founder Shares, subsequent to September 30, 2021.
Prior to the consummation of an initial Business Combination, only holders of shares of Class B common stock will have the right to vote on the election of directors. Holders of shares of Class A common stock and shares of Class B common stock will vote together as a single class on all other matters submitted to a vote of stockholders.
The shares of Class B common stock will automatically convert into shares of Class A common stock at the time of a Business Combination at a ratio such that the number of shares of Class A common stock issuable upon conversion of all Founder Shares will equal, in the aggregate, on an
as-converted
basis
, 20
% of the sum of (i) the total number of common stock issued and outstanding upon completion of the IPO, plus (ii) the total number of shares of Class A common stock issued or deemed issued or issuable upon conversion or exercise of any equity-linked securities or rights issued or deemed issued, by the Company in connection with or in relation to the consummation of a Business Combination, excluding any shares of Class A common stock or equity-linked securities exercisable for or convertible into shares of Class A common stock issued, deemed issued, or to be issued, to any seller in a Business Combination and any Placement Warrants issued to the Sponsor, its affiliates or any member of the management team upon conversion of Working Capital Loans. In no event will the shares of Class B common stock convert into shares of Class A common stock at a rate of less than
one-to-one.
Preferred stock
 — The
Company is authorized to issue 1,000,000 shares of preferred stock with such designations, voting and other rights and preferences as may be determined from time to time by the Company’s board of directors. As of September 30, 2021, there were no shares of preferred stock issued or outstanding.
Warrants -
 The Public Warrants will become exercisable on the later of (a) 30 days after the completion of a Business Combination or (b) 12 months from the closing of the IPO. No warrants will be exercisable for cash unless the Company has an effective and current registration statement covering the common stock issuable upon exercise of the warrants and a current prospectus relating to such common stock. Notwithstanding the foregoing, if a registration statement covering the common stock issuable upon exercise of the Public Warrants is not effective within a specified period following the consummation of a Business Combination, warrant holders may, until such time as there is an effective registration statement and during any period when the Company shall have failed to maintain an effective registration statement, exercise warrants on a cashless basis pursuant to the exemption provided by Section 3(a)(9) of the Securities Act, provided that such exemption is available. If that exemption, or another exemption, is not available, holders will not be able to exercise their warrants on a cashless basis. The Public Warrants will expire five years after the completion of a Business Combination or earlier upon redemption or liquidation.
Once the warrants become exercisable, the Company may redeem the Public Warrants:
 
 
•
 
in whole and not in part;
 
 
 •  
at a price of $0.01 per warrant;
 
 
 •  
upon not less than 30 days’ prior written notice of redemption;
 
 
 •  
if, and only if, the reported last sale price of
Class A 
common stock equals or exceeds $18.00 per share (as adjusted for stock splits, stock dividends, reorganizations and recapitalizations), for any 20 trading days within a 30
-trading-day 
period commencing at any time after the warrants become exercisable and ending on the third business day prior to the notice of redemption to warrant holders; and
 
11
Table of Contents
 
•
 
if, and only if, there is a current registration statement in effect with respect to the shares of Class A common stock underlying the warrants.
If the
Company calls the Public Warrants for redemption, management will have the option to require all holders that wish to exercise the Public Warrants to do so on a “cashless basis,” as described in the warrant agreement.
The Placement
Warrants are identical to the Public Warrants underlying the Units sold in the IPO, except that the Placement Warrants and the common stock issuable upon the exercise of the Placement Warrants will not be transferable, assignable or salable until after the completion of a Business Combination, subject to certain limited exceptions. The Placement Warrants will be redeemable by the Company and exercisable by such holders on the same basis as the Public Warrants.
The exercise price and number of shares of common stock issuable upon exercise of the warrants may be adjusted in certain circumstances including in the event of a stock dividend, extraordinary dividend or recapitalization, reorganization, merger or consolidation. However, the warrants will not be adjusted for issuances of common stock at a price below their respective exercise prices. Additionally, in no event will the Company be required to net cash settle the warrants. If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution from the Company’s assets held outside of the Trust Account with the respect to such warrants. Accordingly, the warrants may expire worthless.
In addition, if the
Company issues additional common stock or equity-linked securities for capital raising purposes in connection with the closing of a Business Combination at an issue price or effective issue price of less than $9.20 per share of common stock (with such issue price or effective issue price to be determined in good faith by the Company’s board of directors, and in the case of any such issuance to the Initial Stockholders or their affiliates, without taking into account any Founder Shares held by them prior to such issuance),
 and (y) t
he aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of a Business Combination on the date of the consummation of a Business Combination (net of redemptions), and (z) the volume
weighted-average 
trading price of the Company’s common stock during the 20
-trading-day 
period starting on the trading day prior to the day on which the Company consummates a Business Combination (such price, the “Market Value”) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the greater of (i) the Market Value or (ii) the price at which the Company issues the additional shares of common stock or equity-linked securities.
Note 8 — Subsequent Events
The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the unaudited condensed financial statements were available to be issued and, except as set forth below, has determined that there have been no events that have occurred that would require adjustments to the disclosures of the unaudited condensed financial statements.
Following the closing of the IPO on October 8, 2021, an amount of $178,500,000 ($10.20
per Unit) from the net proceeds of the sale of the Units in the IPO and the Private Placement was placed in a trust account.
 
12
Table of Contents
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
References in this report (this “Quarterly Report”) to “we,” “us” or the “Company” refer to -Phoenix Biotech Acquisition Corp. References to our “management” or our “management team” refer to our officers and directors, and references to the “Sponsor” refer to Phoenix Biotech Sponsor, LLC. The following discussion and analysis of the Company’s financial condition and results of operations should be read in conjunction with the financial statements and the notes thereto contained elsewhere in this Quarterly Report. Certain information contained in the discussion and analysis set forth below includes forward-looking statements that involve risks and uncertainties.
Special Note Regarding Forward-Looking Statements
This Quarterly Report includes “forward-looking statements” within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act that are not historical facts and involve risks and uncertainties that could cause actual results to differ materially from those expected and projected. All statements, other than statements of historical fact included in this Form
10-Q
including, without limitation, statements in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations” regarding the Company’s financial position, business strategy and the plans and objectives of management for future operations, are forward-looking statements. Words such as “expect,” “believe,” “anticipate,” “intend,” “estimate,” “seek” and variations and similar words and expressions are intended to identify such forward-looking statements. Such forward-looking statements relate to future events or future performance, but reflect management’s current beliefs, based on information currently available. A number of factors could cause actual events, performance or results to differ materially from the events, performance and results discussed in the forward-looking statements. For information identifying important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements, please refer to the Risk Factors section of the Company’s final prospectus filed with the U.S. Securities and Exchange Commission (the “SEC”). The Company’s securities filings can be accessed on the EDGAR section of the SEC’s website at www.sec.gov. Except as expressly required by applicable securities law, the Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.
Overview
Phoenix Biotech Acquisition Corp. was incorporated in Delaware on June 8, 2021. The Company was formed for the purpose of entering into a merger, share exchange, asset acquisition, stock purchase, reorganization or other similar business transaction with one or more businesses that the Company has not yet identified (a “Business Combination”).
We expect to continue to incur significant costs in the pursuit of our acquisition plans. We cannot assure you that our plans to complete a Business Combination will be successful.
Results of Operations
As of September 30, 2021, the Company had not commenced any operations. All activity through September 30, 2021 relates to the Company’s formation and the initial public offering (the “IPO”). The Company will not generate any operating revenues until after the completion of a Business Combination, at the earliest. The Company will generate
non-operating
income in the form of interest income from the proceeds derived from the IPO placed in the Trust Account (defined below).
For the three months ended September 30, 2021, and for the period June 8, 2021 (inception) through September 30, 2021, we had a net loss of $0 and $1,000 respectively which consisted of organizational costs.
Liquidity and Capital Resources
The registration statement for the Company’s IPO was declared effective on October 5, 2021. On October 8, 2021, the Company consummated the IPO of 15,500,000 units (“Units”) (with respect to the Class A common stock included in the Units being offered (the “Public Shares”)) at $10.00 per Unit generating gross proceeds of $155,000,000, which is discussed in Note 3. The company has selected December 31 as its fiscal year end.
 
13
Table of Contents
Simultaneously with the closing of the IPO, the Company consummated the sale of 845,000 units (“Private Placement Units”) at a price of $10.00 per Private Placement Unit in a private placement to the Company’s sponsor, Phoenix Biotech Sponsor, LLC (the “Sponsor”), Cantor Fitzgerald & Co. (Cantor”) and Cohen & Company Capital Markets, a division of J.V.B. Financial Group, LLC (“CCM”), generating gross proceeds of $8,450,000, which is described in Note 4.
Simultaneously with the closing of the IPO, the Company consummated the closing of the sale of 2,000,000 additional Units upon receiving notice of the underwriter’s election to partially exercise its over-allotment option (“Over-allotment Units”), generating additional gross proceeds of $20,000,000 and incurring additional offering costs of $1,400,000 in underwriting fees, all of which is deferred until the completion of the Company’s initial Business Combination. Simultaneously with the exercise of the over-allotment, the Company consummated the Private Placement of an additional 40,000 Private Placement Units to the Sponsor and CCM, generating gross proceeds of $400,000.
Following the closing of the IPO, $178,500,000 ($10.20 per Unit) from the net proceeds of the sale of the Units in the IPO, the Over-allotment Units and the Private Placement Units was placed in a trust account (“Trust Account”) and will be invested in U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act of 1940, as amended (the “Investment Company Act”), with a maturity of 185 days or less or in money market funds meeting the conditions of the Investment Company Act, as determined by the Company, until the earlier of: (i) the completion of a Business Combination and (ii) the distribution of the Trust Account, as described below.
For the period June 8, 2021 (inception) through September 30, 2021, there was $1,000 of cash used in operating activities.
We intend to use substantially all of the funds held in the Trust Account, including any amounts representing interest earned on the Trust Account (less taxes payable), to complete our Business Combination. To the extent that our capital stock or debt is used, in whole or in part, as consideration to complete our Business Combination, the remaining proceeds held in the Trust Account will be used as working capital to finance the operations of the target business or businesses, make other acquisitions and pursue our growth strategies.
As of September 30, 2021, we had no cash.
In order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company’s officers and directors may, but are not obligated to, loan the Company funds as may be required (“Working Capital Loans”). If the Company completes a Business Combination, the Company may repay the Working Capital Loans out of the proceeds of the Trust Account released to the Company. Otherwise, the Working Capital Loans may be repaid only out of funds held outside the Trust Account. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans, but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. Except for the foregoing, the terms of such Working Capital Loans, if any, have not been determined and no written agreements exist with respect to such loans. The Working Capital Loans would either be repaid upon consummation of a Business Combination, without interest, or, at the lender’s discretion, up to $1,500,000 of such Working Capital Loans may be converted into units of the post-Business Combination entity at a price of $10.00 per unit. The units would be identical to the Private Placement Units. As of September 30, 2021, the Company had no outstanding borrowings under the Working Capital Loans.
We do not believe we will need to raise additional funds in order to meet the expenditures required for operating our business. However, if our estimate of the costs of identifying a target business, undertaking
in-depth
due diligence and negotiating a Business Combination are less than the actual amount necessary to do so, we may have insufficient funds available to operate our business prior to our Business Combination. Moreover, we may need to obtain additional financing either to complete our Business Combination or because we become obligated to redeem a significant number of our Public Shares upon consummation of our Business Combination, in which case we may issue additional securities or incur debt in connection with such Business Combination.
Off-Balance
Sheet Arrangements
We have no obligations, assets or liabilities, which would be considered
off-balance
sheet arrangements as of September 30, 2021. We do not participate in transactions that create relationships with entities or financial partnerships, often referred to as variable interest entities, which would have been established for the purpose of facilitating
off-balance
sheet arrangements. We have not entered into any
off-balance
sheet financing arrangements, established any special purpose entities, guaranteed any debt or commitments of other entities, or purchased any
non-financial
assets.
 
14
Table of Contents
Contractual obligations
We do not have any long-term debt, capital lease obligations, operating lease obligations or long-term liabilities.
The underwriter is entitled to deferred underwriting commissions of $9,150,000 in the aggregate. The deferred fee will become payable to the underwriter from the amounts held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement.
JOBS Act
On April 5, 2012, the JOBS Act was signed into law. The JOBS Act contains provisions that, among other things, relax certain reporting requirements for qualifying public companies. We will qualify as an “emerging growth company” and under the JOBS Act will be allowed to comply with new or revised accounting pronouncements based on the effective date for private (not publicly traded) companies. We are electing to delay the adoption of new or revised accounting standards, and as a result, we may not comply with new or revised accounting standards on the relevant dates on which adoption of such standards is required for
non-emerging
growth companies. As such, our financial statements may not be comparable to companies that comply with public company effective dates.
Additionally, we are in the process of evaluating the benefits of relying on the other reduced reporting requirements provided by the JOBS Act. Subject to certain conditions set forth in the JOBS Act, if, as an “emerging growth company,” we choose to rely on such exemptions we may not be required to, among other things, (i) provide an auditor’s attestation report on our system of internal control over financial reporting pursuant to Section 404 of the Sarbanes-Oxley Act, (ii) provide all of the compensation disclosure that may be required of
non-emerging
growth public companies under the Dodd-Frank Wall Street Reform and Consumer Protection Act, (iii) comply with any requirement that may be adopted by the PCAOB regarding mandatory audit firm rotation or a supplement to the auditor’s report providing additional information about the audit and the financial statements (auditor discussion and analysis) and (iv) disclose certain executive compensation related items such as the correlation between executive compensation and performance and comparisons of executive compensation to median employee compensation. These exemptions will apply for a period of five years following the completion of our IPO or until we are no longer an “emerging growth company,” whichever is earlier.
Critical Accounting Policies
The preparation of unaudited condensed financial statements and related disclosures in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and income and expenses during the periods reported. Actual results could materially differ from those estimates. We have identified the following critical accounting policies:
Common stock Subject to Possible Redemption
We account for our common stock subject to possible redemption in accordance with the guidance in Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing Liabilities from Equity.” Common stock subject to mandatory redemption is classified as a liability instrument and is measured at fair value. Conditionally redeemable common stock (including common stock that features redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within our control) is classified as temporary equity. At all other times, common stock are classified as stockholders’ equity. Our common stock features certain redemption rights that are considered to be outside of our control and subject to occurrence of uncertain future events. Accordingly, common stock subject to possible redemption is presented as temporary equity, outside of the stockholders’ equity section of our condensed balance sheets. The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable common stock to equal the redemption value at the end of each reporting period. Increases or decreases in the carrying amount of redeemable common stock are affected by charges against additional paid in capital and accumulated deficit.
Management does not believe that any other recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on our condensed financial statements.
 
15
Table of Contents
Item 3. Quantitative and Qualitative Disclosures About Market Risk
As of September 30, 2021, we were not subject to any market or interest rate risk. The net proceeds held in the Trust Account have been invested in U.S. government treasury bills, notes or bonds with a maturity of 185 days or less, or in certain money market funds that invest solely in U.S. treasuries. Due to the short-term nature of these investments, we believe there will be no associated material exposure to interest rate risk.
Item 4. Controls and Procedures
Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure.
Evaluation of Disclosure Controls and Procedures
As required by Rules
13a-15
and
15d-15
under the Exchange Act, our Chief Executive Officer and Chief Financial Officer carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of September 30, 2021. Based upon their evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures (as defined in Rules
13a-15
(e) and
15d-15
(e) under the Exchange Act) were effective.
Changes in Internal Control Over Financial Reporting
During the most recently completed fiscal quarter, there has been no change in our internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
PART II—OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
None.
ITEM 1A. RISK FACTORS
Factors that could cause our actual results to differ materially from those in this Quarterly Report are any of the risks described in our final prospectus, as amended, for our IPO filed with the SEC on October 8, 2021. Any of these factors could result in a significant or material adverse effect on our results of operations or financial condition. Additional risk factors not presently known to us or that we currently deem immaterial may also impair our business or results of operations. As of the date of this Quarterly Report, there have been no material changes to the risk factors disclosed in our final prospectus for our IPO filed with the SEC on October 8, 2021.
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
The securities in the IPO were registered under the Securities Act on a registration statement on Form S-1 (No. 333-259491). The registration statement for the Company’s IPO was declared effective on October 5, 2021. On October 8, 2021, the Company consummated the IPO of 15,500,000 units (“Units”) (with respect to the Class A common stock included in the Units being offered (the “Public Shares”)) at $10.00 per Unit generating gross proceeds of $155,000,000. Cantor Fitzgerald & Co. (“Cantor”) acted as sole book-running manager of the IPO.
 
16
Table of Contents
Simultaneously with the closing of the IPO, the Company consummated the sale of 845,000 units (“Private Placement Units”) at a price of $10.00 per Private Placement Unit in a private placement to the Company’s sponsor, Phoenix Biotech Sponsor, LLC (the “Sponsor”), Cantor Fitzgerald & Co. (Cantor”) and Cohen & Company Capital Markets, a division of J.V.B. Financial Group, LLC (“CCM”), generating gross proceeds of $8,450,000. The issuance was made pursuant to the exemption from registration contained in Section 4(a)(2) of the Securities Act.
Offering costs for the IPO amounted to $11,329,318, consisting of $2,635,000 of underwriting fees, $7,750,000 of deferred underwriting fees payable (which are held in the Trust Account (defined below)) and $944,318 of other costs. The $9,150,000 of deferred underwriting fee payable is contingent upon the consummation of a Business Combination by January 8, 2023, subject to the terms of the underwriting agreement.
Simultaneously with the closing of the IPO, the Company consummated the closing of the sale of 2,000,000 additional Units upon receiving notice of the underwriter’s election to partially exercise its over-allotment option (“Over-allotment Units”), generating additional gross proceeds of $20,000,000 and incurring additional offering costs of $1,400,000 in underwriting fees, all of which is deferred until the completion of the Company’s initial business combination. Simultaneously with the exercise of the over-allotment, the Company consummated the Private Placement of an additional 40,000 Private Placement Units to the Sponsor and CCM, generating gross proceeds of $400,000.
Following the closing of the IPO, $178,500,000 ($10.20 per Unit) from the net proceeds of the sale of the Units in the IPO, the Over-allotment Units and the Private Placement Units was placed in a trust account (“Trust Account”) and will be invested in U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act of 1940, as amended (the “Investment Company Act”), with a maturity of 185 days or less or in money market funds meeting the conditions of the Investment Company Act, as determined by the Company, until the earlier of: (i) the completion of a Business Combination and (ii) the distribution of the Trust Account.
We paid a total of $3,100,000 underwriting discounts and commissions and $465,000 for other offering costs and expenses related to the IPO. In addition, the underwriter agreed to defer $9,150,000 in underwriting discounts and commissions.
For a description of the use of the proceeds generated in our IPO, see Part I, Item 2 of this Quarterly Report.
ITEM 3. DEFAULTS UPON SENIOR SECURITIES
None.
ITEM 4. MINE SAFETY DISCLOSURES
Not applicable.
ITEM 5. OTHER INFORMATION
None.
ITEM
6.
EXHIBITS
The following exhibits are filed as part of, or incorporated by reference into, this Quarterly Report on Form 10-Q.
 
No.
   
Description of Exhibit
3.1    Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K filed with the SEC on October 12, 2021).
3.2   
4.1    Specimen Unit Certificate (incorporated by reference to Exhibit 4.1 filed with the Form S-1 filed by the Registrant on September 21, 2021).
4.2   
4.3   
4.4   
31.1*    Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rules 13a-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2*    Certification of Principal Financial Officer Pursuant to Securities Exchange Act Rules 13a-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1*    Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2*    Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS*    XBRL Instance Document
101.SCH*    XBRL Taxonomy Extension Schema Document
101.CAL*    XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF*    XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*    XBRL Taxonomy Extension Labels Linkbase Document
101.PRE*    XBRL Taxonomy Extension Presentation Linkbase Document
104    Cover Page Interactive Data File - the cover page interactive data is embedded within the Inline XBRL document or included within the Exhibit 101 attachments.
 
17
Table of Contents
SIGNATURES
In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
   
PHOENIX BIOTECH ACQUISITION CORP.
Date: November 19, 2021     By:   /s/ Chris Ehrlich
    Name:   Chris Ehrlich
    Title:   Chief Executive Officer and Director
      (Principal Executive Officer)
 
Date: November 19, 2021     By:   /s/ Daniel Geffken
    Name:   Daniel Geffken
    Title:   Chief Financial Officer and Director
      (Principal Financial and Accounting Officer)
 
18
TABLE OF CONTENTS
Item 1. Financial Statements Phoenix Biotech Acquisition Corp. Condensed Balance Sheet (unaudited) September 30, 2021Item 1. Financial StatementsNote 1 Description Of Organization and Business OperationsNote 2 Summary Of Significant Accounting PoliciesNote 3 Initial Public OfferingNote 4 Private PlacementNote 5 Related Party TransactionsNote 6 Commitments and ContingenciesNote 7 Stockholder S EquityNote 8 Subsequent EventsItem 2. Management S Discussion and Analysis Of Financial Condition and Results Of OperationsItem 3. Quantitative and Qualitative Disclosures About Market RiskItem 4. Controls and ProceduresPart II Other InformationItem 1. Legal ProceedingsItem 1A. Risk FactorsItem 2. Unregistered Sales Of Equity Securities and Use Of ProceedsItem 3. Defaults Upon Senior SecuritiesItem 4. Mine Safety DisclosuresItem 5. Other InformationItem 6. Exhibits

Exhibits

3.1 Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 of the Companys Current Report on Form8-K filed with the SEC on October 12, 2021). 3.2 Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2(b) filed with the Form S-1 filed by the Registrant on September13, 2021). 4.1 Specimen Unit Certificate (incorporated by reference to Exhibit 4.1 filed with the Form S-1 filed by the Registrant on September 21, 2021). 4.2 Specimen Class A Common Stock Certificate (incorporated by reference to Exhibit 4.2 filed with the Form S-1 filed by the Registrant on September 21, 2021). 4.3 Specimen Warrant Certificate (included in Exhibit 4.4). 4.4 Warrant Agreement dated October 5, 2021, between the Company and Continental Stock Transfer & Trust Company (incorporated by reference to Exhibit 4.1 of the Companys Current Report on Form 8-K filed with the SEC on October 12, 2021). 31.1* Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rules 13a-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 31.2* Certification of Principal Financial Officer Pursuant to Securities Exchange Act Rules 13a-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 32.1* Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of theSarbanes-OxleyAct of 2002 32.2* Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of theSarbanes-OxleyAct of 2002